Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Paperless medical clerking: are we still documenting what matters?

El-Masry A, Kelly P, Visanji S, Hawksley A, Farber L.

Future Healthc J. 2019 Jun;6(Suppl 2):8. doi: 10.7861/futurehosp.6-2s-s8. No abstract available.

3.

Ticket to spawn: Combining economic and genetic data to evaluate the effect of climate and demographic structure on spawning distribution in Atlantic cod.

Langangen Ø, Färber L, Stige LC, Diekert FK, Barth JMI, Matschiner M, Berg PR, Star B, Stenseth NC, Jentoft S, Durant JM.

Glob Chang Biol. 2019 Jan;25(1):134-143. doi: 10.1111/gcb.14474. Epub 2018 Oct 30.

PMID:
30300937
4.

[Hermann Oppenheim. Comments on his life and works].

Färber L, Lattrell B, Adloff AK, Welsh T, Heeschen V, Hartung HP.

Nervenarzt. 2016 Oct;87(10):1100-1106. German.

PMID:
27389602
5.

WHAT IS EFFECTIVE IN THE THERAPEUTIC PROCESS? A ROUND TABLE DISCUSSION. 1957.

Farber LH.

Am J Psychoanal. 2015 Jun;75(2):203-10. doi: 10.1057/ajp.2015.7. No abstract available.

PMID:
26177765
6.

Sunscreening fungal pigments influence the vertical gradient of pendulous lichens in boreal forest canopies.

Färber L, Sølhaug KA, Esseen PA, Bilger W, Gauslaa Y.

Ecology. 2014 Jun;95(6):1464-71.

PMID:
25039211
7.

Surgical blues: vitreous staining with trypan blue during cataract surgery.

Wang BZ, Forward H, Farber L, Chiu D, Chandra A.

Clin Exp Ophthalmol. 2014 Nov;42(8):788-9. doi: 10.1111/ceo.12320. Epub 2014 Jun 23. No abstract available.

PMID:
24617295
8.

A new methodology for high drug loading wet granulation formulation development.

Cai L, Farber L, Zhang D, Li F, Farabaugh J.

Int J Pharm. 2013 Jan 30;441(1-2):790-800. doi: 10.1016/j.ijpharm.2012.09.052. Epub 2012 Oct 9.

PMID:
23058927
9.

Renal cell carcinoma deep sequencing: recent developments.

Farber LJ, Furge K, Teh BT.

Curr Oncol Rep. 2012 Jun;14(3):240-8. doi: 10.1007/s11912-012-0230-3. Review.

PMID:
22535504
10.

Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography.

Hopper I, Kemp W, Porapakkham P, Sata Y, Condon E, Skiba M, Farber L, Porapakkham P, Williams TJ, Menahem S, Roberts S, Krum H.

Eur J Heart Fail. 2012 Jun;14(6):621-7. doi: 10.1093/eurjhf/hfs044. Epub 2012 Apr 20.

11.

Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer.

Farber L, Efrati E, Elkin H, Peerless Y, Sabo E, Ben-Izhak O, Hershkovitz D.

Virchows Arch. 2011 Nov;459(5):487-93. doi: 10.1007/s00428-011-1158-y. Epub 2011 Oct 21.

PMID:
22016105
12.

The effects of aging on contour discrimination in clutter.

Roudaia E, Farber LE, Bennett PJ, Sekuler AB.

Vision Res. 2011 May 11;51(9):1022-32. doi: 10.1016/j.visres.2011.02.015. Epub 2011 Feb 21.

13.

Species-specific difference in expression and splice-site choice in Inpp5b, an inositol polyphosphate 5-phosphatase paralogous to the enzyme deficient in Lowe Syndrome.

Bothwell SP, Farber LW, Hoagland A, Nussbaum RL.

Mamm Genome. 2010 Oct;21(9-10):458-66. doi: 10.1007/s00335-010-9281-7. Epub 2010 Sep 26.

14.

[Germany's Novartis Chief proposes "More competition through decentralized contracts"].

Kosche D, Färber L.

MMW Fortschr Med. 2010 Aug 12;152(31-33):6-7. German. No abstract available.

PMID:
20828056
15.

The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA.

Farber LJ, Kort EJ, Wang P, Chen J, Teh BT.

Mol Carcinog. 2010 Mar;49(3):215-23. doi: 10.1002/mc.20591.

PMID:
19908240
16.

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.

Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M.

J Immunother. 2008 Jul-Aug;31(6):569-76. doi: 10.1097/CJI.0b013e318177a4ba.

PMID:
18528297
17.

The E2F3-Oncomir-1 axis is activated in Wilms' tumor.

Kort EJ, Farber L, Tretiakova M, Petillo D, Furge KA, Yang XJ, Cornelius A, Teh BT.

Cancer Res. 2008 Jun 1;68(11):4034-8. doi: 10.1158/0008-5472.CAN-08-0592.

18.

Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction.

Jhaveri JD, Rush SC, Kostroff K, Derisi D, Farber LA, Maurer VE, Bosworth JL.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):859-65. doi: 10.1016/j.ijrobp.2008.01.055. Epub 2008 May 28.

PMID:
18472362
19.

Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice.

Wang P, Bowl MR, Bender S, Peng J, Farber L, Chen J, Ali A, Zhang Z, Alberts AS, Thakker RV, Shilatifard A, Williams BO, Teh BT.

Mol Cell Biol. 2008 May;28(9):2930-40. doi: 10.1128/MCB.00654-07. Epub 2008 Jan 22.

20.

Unified compaction curve model for tensile strength of tablets made by roller compaction and direct compression.

Farber L, Hapgood KP, Michaels JN, Fu XY, Meyer R, Johnson MA, Li F.

Int J Pharm. 2008 Jan 4;346(1-2):17-24. Epub 2007 Jun 22.

PMID:
17689211
21.

Don't miss these business deductions.

Farber L.

Med Econ. 2007 Mar 2;84(5):48-51. No abstract available.

PMID:
17425277
22.

Experimental study of wet granulation in fluidized bed: impact of the binder properties on the granule morphology.

Rajniak P, Mancinelli C, Chern RT, Stepanek F, Farber L, Hill BT.

Int J Pharm. 2007 Apr 4;334(1-2):92-102. Epub 2006 Nov 10.

PMID:
17207948
23.

Parafibromin inhibits cancer cell growth and causes G1 phase arrest.

Zhang C, Kong D, Tan MH, Pappas DL Jr, Wang PF, Chen J, Farber L, Zhang N, Koo HM, Weinreich M, Williams BO, Teh BT.

Biochem Biophys Res Commun. 2006 Nov 10;350(1):17-24. Epub 2006 Sep 7.

PMID:
16989776
24.

The effect of missense mutations in the RhoGAP-homology domain on ocrl1 function.

Lichter-Konecki U, Farber LW, Cronin JS, Suchy SF, Nussbaum RL.

Mol Genet Metab. 2006 Sep-Oct;89(1-2):121-8. Epub 2006 Jun 13.

PMID:
16777452
26.

Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.

Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA.

Oncology. 2005;69(5):372-83. Epub 2005 Nov 24.

PMID:
16319508
27.

Micro-mechanical properties of drying material bridges of pharmaceutical excipients.

Farber L, Tardos GI, Michaels JN.

Int J Pharm. 2005 Dec 8;306(1-2):41-55. Epub 2005 Nov 7.

PMID:
16274947
28.

Breaking the cycles of violence.

Dawes J, Murphy P, Farber L, Parkes CM, Farber S, O'Connor P, Kallenberg K, Weiss R, Meijburg H, Benoliel JQ, de Monnink HJ, Snyder B; Work Group of the International Work Group on Death, Dying and Bereavement.

Death Stud. 2005 Sep;29(7):585-600.

PMID:
16136707
29.

Three generations of cyclosporine a formulations: an in vitro comparison.

Thomas K, Koelwel C, Machei U, Färber L, Göpferich A.

Drug Dev Ind Pharm. 2005 May;31(4-5):357-66.

PMID:
16093201
30.

Financial survey. Is your net worth keeping pace?

Farber L.

Med Econ. 2005 Jun 17;82(12):50-6. No abstract available.

PMID:
16045268
31.

The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway.

Vega Lde L, Muñoz E, Calzado MA, Lieb K, Candelario-Jalil E, Gschaidmeir H, Färber L, Mueller W, Stratz T, Fiebich BL.

Biochem Pharmacol. 2005 Aug 1;70(3):369-80.

PMID:
15922994
32.

The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience.

Kohnen R, Färber L, Späth M.

Scand J Rheumatol Suppl. 2004;119:67-71.

PMID:
15515419
33.

Treatment of fibromyalgia with tropisetron--dose and efficacy correlations.

Späth M, Stratz T, Färber L, Haus U, Pongratz D.

Scand J Rheumatol Suppl. 2004;119:63-6. Review.

PMID:
15515418
34.

Spectrum of use and tolerability of 5-HT3 receptor antagonists.

Haus U, Späth M, Färber L.

Scand J Rheumatol Suppl. 2004;119:12-8. Review.

PMID:
15515406
35.

Physiology and pathophysiology of the 5-HT3 receptor.

Färber L, Haus U, Späth M, Drechsler S.

Scand J Rheumatol Suppl. 2004;119:2-8. Review.

PMID:
15515404
36.

Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.

Späth M, Stratz T, Neeck G, Kötter I, Hammel B, Amberger CC, Haus U, Färber L, Pongratz D, Müller W.

Scand J Rheumatol. 2004;33(4):267-70.

PMID:
15370724
37.

Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma.

Ariyan S, Ariyan C, Farber LR, Fischer DS, Flynn SD, Truini C.

J Am Coll Surg. 2004 Jun;198(6):924-32.

PMID:
15194074
38.

Living liver donation: a survey of the attitudes of the public in Great Britain.

Neuberger J, Farber L, Corrado M, O'Dell C.

Transplantation. 2003 Oct 27;76(8):1260-4.

PMID:
14578769
39.

Discussion on the biologic therapy of inflammatory bowel disease.

Merger M, Herfarth H, Scholmerich J, Andus T, Färber L.

Gastroenterology. 2003 Jun;124(7):2005-6. No abstract available.

PMID:
12812200
40.

Characterization of crystalline drug nanoparticles using atomic force microscopy and complementary techniques.

Shi HG, Farber L, Michaels JN, Dickey A, Thompson KC, Shelukar SD, Hurter PN, Reynolds SD, Kaufman MJ.

Pharm Res. 2003 Mar;20(3):479-84.

PMID:
12669972
41.
42.

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G.

J Clin Invest. 2002 Nov;110(9):1309-18.

43.
44.

Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.

Kees F, Färber L, Bucher M, Mair G, Mörike K, Grobecker H.

Br J Clin Pharmacol. 2001 Dec;52(6):705-7.

45.

Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.

Färber L, Stratz TH, Brückle W, Späth M, Pongratz D, Lautenschläger J, Kötter I, Zöller B, Peter HH, Neeck G, Welzel D, Müller W; German Fibromyalgia Study Group.

Int J Clin Pharmacol Res. 2001;21(1):1-13.

PMID:
11708570
46.

Make the most of the new tax law.

Farber L.

Med Econ. 2001 Sep 17;78(18):22-4, 27-8. No abstract available.

PMID:
11601167
47.

Financial survey. Retirement funding falls again.

Farber L.

Med Econ. 2001 Jul 23;78(14):78-80, 85-6, 91-2.

PMID:
11499293
48.

Fibromyalgia treatment with intravenous tropisetron administration.

Stratz T, Färber L, Varga B, Baumgartner C, Haus U, Müller W.

Drugs Exp Clin Res. 2001;27(3):113-8.

PMID:
11447769
49.

A slip in net worth.

Farber L.

Med Econ. 2001 May 21;78(10):122-4, 127-30, 135. No abstract available.

PMID:
11409265
50.

A dosimetric comparison of conventional vs conformal external beam irradiation of a stented coronary artery utilizing a new fluoroscopic imaging detector system.

Farber LA, Bloch P, Yorke ED, Stevens CW, Herrmann H, Ruffer JE.

Cardiovasc Radiat Med. 1999 Jan-Mar;1(1):80-5.

PMID:
11272361

Supplemental Content

Loading ...
Support Center